Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016 (2016), Article ID 1858202, 6 pages
http://dx.doi.org/10.1155/2016/1858202
Research Article

Immunological Aspects of Fulminant Type 1 Diabetes in Chinese

1Diabetes Center, 2nd Xiangya Hospital and Institute of Metabolism and Endocrinology, Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, 139 Renmin Middle Road, Changsha, Hunan 410011, China
2The Center for Medical Research, 2nd Xiangya Hospital, Central South University, 139 Renmin Middle Road, Changsha, Hunan 410011, China

Received 14 July 2015; Revised 15 January 2016; Accepted 18 January 2016

Academic Editor: Kurt Blaser

Copyright © 2016 Zhen Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, “Report of the expert committee on the diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 20, no. 7, pp. 1183–1197, 1997. View at Publisher · View at Google Scholar
  2. K. G. M. M. Alberti and P. Z. Zimmet, “Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation,” Diabetic Medicine, vol. 15, no. 7, pp. 539–553, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. J.-F. Bach, “Insulin-dependent diabetes mellitus as an autoimmune disease,” Endocrine Reviews, vol. 15, no. 4, pp. 516–542, 1994. View at Publisher · View at Google Scholar · View at Scopus
  4. G. F. Bottazzo, A. Florin-Christensen, and D. Doniach, “Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies,” The Lancet, vol. 304, no. 7892, pp. 1279–1283, 1974. View at Publisher · View at Google Scholar · View at Scopus
  5. G. S. Eisenbarth, “Type I diabetes mellitus. A chronic autoimmune disease,” The New England Journal of Medicine, vol. 314, no. 21, pp. 1360–1368, 1986. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Sia, “Imbalance in Th cell polarization and its relevance in type 1 diabetes mellitus,” The Review of Diabetic Studies, vol. 2, no. 4, pp. 182–182, 2005. View at Publisher · View at Google Scholar
  7. C. J. Hedegaard, M. Krakauer, K. Bendtzen, H. Lund, F. Sellebjerg, and C. H. Nielsen, “T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis,” Immunology, vol. 125, no. 2, pp. 161–169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Shao, F. He, Y. Yang, G. Yuan, M. Zhang, and X. Yu, “Th17 cells in type 1 diabetes,” Cellular Immunology, vol. 280, no. 1, pp. 16–21, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. E. M. Shevach, “Certified professionals: CD4+CD25+ suppressor T cells,” The Journal of Experimental Medicine, vol. 193, no. 11, pp. F41–F45, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Imagawa, T. Hanafusa, J.-I. Miyagawa, and Y. Matsuzawa, “A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies,” The New England Journal of Medicine, vol. 342, no. 5, pp. 301–307, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Imagawa, T. Hanafusa, Y. Uchigata et al., “Fulminant type 1 diabetes: a nationwide survey in Japan,” Diabetes Care, vol. 26, no. 8, pp. 2345–2352, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Tanaka, T. Kobayashi, and T. Momotsu, “A novel subtype of type 1 diabetes mellitus,” The New England Journal of Medicine, vol. 342, no. 24, pp. 1835–1837, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Kotani, M. Nagata, A. Imagawa et al., “T lymphocyte response against pancreatic cell antigens in fulminant Type 1 diabetes,” Diabetologia, vol. 47, no. 7, pp. 1285–1291, 2004. View at Google Scholar · View at Scopus
  14. S. Tanaka, Y. Nishida, K. Aida et al., “Enterovirus infection, CXC chemokine ligand 10 (CXCL10), and CXCR3 circuit: a mechanism of accelerated β-cell failure in fulminant type 1 diabetes,” Diabetes, vol. 58, no. 10, pp. 2285–2291, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Haseda, A. Imagawa, Y. Murase-Mishiba et al., “Low CTLA-4 expression in CD4+ helper T-cells in patients with fulminant type 1 diabetes,” Immunology Letters, vol. 139, no. 1-2, pp. 80–86, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Zheng, Z. Zhou, L. Yang et al., “Fulminant type 1 diabetes mellitus exhibits distinct clinical and autoimmunity features from classical type 1 diabetes mellitus in Chinese,” Diabetes/Metabolism Research and Reviews, vol. 27, no. 1, pp. 70–78, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. Wang, Y. Zheng, C. Hou et al., “DNA methylation impairs TLR9 induced Foxp3 expression by attenuating IRF-7 binding activity in fulminant type 1 diabetes,” Journal of Autoimmunity, vol. 41, pp. 50–59, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Kotani, M. Nagata, H. Moriyama et al., “Detection of GAD65-reactive T-cells in type 1 diabetes by immunoglobulin-free ELISPOT assays,” Diabetes Care, vol. 25, no. 8, pp. 1390–1397, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Aggarwal and A. L. Gurney, “IL-17: prototype member of an emerging cytokine family,” Journal of Leukocyte Biology, vol. 71, no. 1, 8 pages, 2002. View at Google Scholar · View at Scopus
  20. C. Dong, “TH17 cells in development: an updated view of their molecular identity and genetic programming,” Nature Reviews Immunology, vol. 8, no. 5, pp. 337–348, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. I. I. Ivanov, B. S. McKenzie, L. Zhou et al., “The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells,” Cell, vol. 126, no. 6, pp. 1121–1133, 2006. View at Publisher · View at Google Scholar · View at Scopus